Amoxicillin 875mg is a high‑strength aminopenicillin formulation used in adults for moderate to severe bacterial infections requiring stronger beta‑lactam exposure. As a tablet‑only dosage, it provides a higher amoxicillin load per administration compared with 500mg and 250mg strengths, supporting more robust coverage against common respiratory and skin pathogens. The mechanism remains consistent across all strengths — inhibition of bacterial cell‑wall synthesis through binding to penicillin‑binding proteins, leading to structural weakening and cell lysis.
Clinically, the 875mg dose is selected for adult patients when infection severity, bacterial load, or site penetration demands a higher systemic concentration. This includes acute bacterial sinusitis, lower respiratory infections such as bronchitis and community‑acquired pneumonia, as well as cellulitis and other skin/soft‑tissue infections. Twice‑daily administration is standard, offering convenient scheduling while maintaining therapeutic levels.
Choosing 875mg instead of 500mg typically reflects clinical judgment regarding infection severity, risk of treatment failure, or need for stronger first‑line coverage. Safety considerations remain aligned with other strengths, including gastrointestinal effects, hypersensitivity reactions, and beta‑lactam allergy profiles, detailed further in Side Effects and Interactions. For broader context, comparisons across strengths and formulations can be explored through amoxicillin dosage guidance and beta‑lactam antibiotic use cases.
Amoxicillin 875mg is a high‑dose aminopenicillin antibiotic within the beta‑lactam class, formulated specifically for adult patients requiring stronger antimicrobial exposure. As a semi‑synthetic penicillin derivative, it inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, causing structural weakening and eventual lysis. The 875mg strength is available exclusively as oral tablets, offering predictable absorption and convenient twice‑daily administration for sustained therapeutic levels in moderate to severe infections.
Clinically, the 875mg dose is selected when infection severity or bacterial load necessitates higher systemic concentrations than those provided by lower strengths. It is commonly prescribed for acute bacterial sinusitis, lower respiratory infections, and community‑acquired pneumonia, where robust beta‑lactam exposure improves treatment reliability. The dose is also used for skin and soft‑tissue infections, including cellulitis, due to its dependable penetration into dermal and subcutaneous tissues.
Compared with standard 500mg regimens, the 875mg formulation is preferred when clinicians anticipate increased risk of treatment failure, require stronger first‑line coverage, or aim to reduce dosing frequency without compromising efficacy. Its safety profile aligns with other amoxicillin strengths, maintaining predictable gastrointestinal tolerability and established hypersensitivity considerations within the broader beta‑lactam family.
Amoxicillin 875mg is chosen for adult patients when infection severity, bacterial load, or risk of treatment failure requires stronger beta‑lactam exposure than standard regimens. This high‑strength option is frequently used in cases where inflammation, purulent discharge, or systemic symptoms indicate a more aggressive infectious process. Clinicians rely on the 875mg dose when moderate infections begin trending toward severe presentations, or when pathogen density suggests that lower strengths may not achieve adequate tissue penetration or sustained therapeutic levels.
The dose is commonly prescribed for acute bacterial sinusitis, where mucosal obstruction and high bacterial burden demand stronger antimicrobial coverage. It is also used in lower respiratory infections such as bronchitis, particularly when symptoms intensify or sputum production increases. In community‑acquired pneumonia, the 875mg strength is often preferred over 500mg due to the need for reliable lung tissue penetration and higher systemic concentrations.
Overall, 875mg is selected when 500mg is insufficient to control infection progression, when rapid symptom stabilization is desired, or when clinical judgment anticipates elevated bacterial load. Its use reflects a balance between stronger antimicrobial pressure and predictable tolerability within the beta‑lactam class.
Adult dosing principles for amoxicillin 875mg center on maintaining consistent therapeutic concentrations while balancing convenience and tolerability. The 875mg strength is typically administered twice daily, a schedule that supports stable beta‑lactam exposure and simplifies adherence for patients managing moderate to severe infections. Frequency is determined by pharmacokinetic behavior, including rapid absorption and predictable distribution across respiratory and soft‑tissue sites.
Infection severity plays a central role in selecting the 875mg dose. When clinical indicators suggest elevated bacterial load, deeper tissue involvement, or risk of treatment failure, clinicians may transition patients from 500mg to 875mg to ensure stronger antimicrobial pressure. This escalation is common in worsening respiratory infections, persistent sinus inflammation, or early pneumonia presentations where higher systemic concentrations improve reliability.
The following table outlines typical use‑cases for the 875mg strength across common adult infections. These are general clinical patterns rather than individualized recommendations, reflecting how severity and symptom progression influence dosing decisions.
| Condition | Typical Use | Notes |
|---|---|---|
| Sinusitis | Adults | High-strength option |
| Bronchitis | Adults | Used when symptoms are stronger |
| Pneumonia | Adults | Often preferred over 500mg |
Amoxicillin 875mg is manufactured exclusively as oral tablets, a format chosen to ensure stable dosing, predictable absorption, and convenient administration for adult patients. Higher‑strength formulations require compact, controlled delivery, and tablets provide the structural integrity needed to contain larger amounts of active ingredient without compromising dissolution or bioavailability.
Tablets offer several practical advantages for the 875mg dose. They maintain consistent pharmacokinetic performance, delivering reliable systemic concentrations essential for treating moderate to severe infections. Their solid form also supports gradual disintegration, enabling efficient absorption in the gastrointestinal tract and reducing variability associated with liquid formulations. For adults, tablets simplify adherence by providing a clear, twice‑daily regimen aligned with typical clinical use.
The exclusive tablet format also reflects manufacturing considerations: higher‑dose suspensions or chewable forms would require large volumes or impractical excipient ratios. Tablets remain the most efficient and clinically appropriate vehicle for delivering the 875mg strength, ensuring both convenience and therapeutic reliability across respiratory, ENT, and skin infection indications.
Amoxicillin 875mg is widely used for adult patients requiring stronger antimicrobial coverage across respiratory, ENT, and skin infections. Its high‑strength profile makes it suitable for acute bacterial sinusitis, where mucosal obstruction and elevated bacterial load demand robust beta‑lactam exposure. The dose is also common in bronchitis, particularly when symptoms intensify or sputum production increases, indicating deeper airway involvement.
In community‑acquired pneumonia, the 875mg strength is often preferred due to its reliable lung tissue penetration and higher systemic concentrations. Beyond respiratory infections, amoxicillin 875mg is used for skin infections such as cellulitis, where predictable soft‑tissue distribution supports effective treatment of dermal and subcutaneous bacterial involvement.
The table below summarizes typical indications for the 875mg dose, reflecting common clinical patterns rather than individualized treatment guidance.
| Condition | Use | Notes |
|---|---|---|
| Sinusitis | Adults | High-strength recommended |
| Bronchitis | Adults | For more severe cases |
| Pneumonia | Adults | Often preferred |
Amoxicillin is available in multiple strengths, each serving a distinct clinical role depending on infection severity, bacterial load, and patient‑specific considerations. The 250mg dose is typically used for mild infections or situations where lower systemic exposure is sufficient. It is also common in step‑down therapy or in patients with reduced tolerance to higher strengths. The 500mg dose represents a standard adult regimen for moderate infections, offering balanced antimicrobial pressure and predictable tolerability. When symptoms intensify or deeper tissue involvement is suspected, clinicians may escalate therapy from 500mg to the high‑strength 875mg option.
The 875mg dose is reserved for severe infections or cases where lower strengths may not achieve adequate tissue penetration or sustained therapeutic levels. It is also selected when bacterial burden is high or when clinical progression suggests that 250mg or 500mg may be insufficient. This escalation reflects the need for stronger beta‑lactam exposure while maintaining convenient twice‑daily dosing.
| Strength | Best Use | Notes |
|---|---|---|
| 250mg | Children/Adults | Mild infections |
| 500mg | Adults | Moderate infections |
| 875mg | Adults | Severe infections |
Amoxicillin 875mg shares the same safety profile as other strengths, with predictable gastrointestinal and hypersensitivity reactions characteristic of beta‑lactam antibiotics. GI responses such as nausea, loose stools, abdominal discomfort, and mild diarrhea are among the most frequently reported effects. These reactions typically reflect changes in gut flora and are generally self‑limiting. More pronounced GI symptoms may occur in sensitive individuals or during treatment of high‑burden infections.
Dermatologic reactions, including mild rash, can appear during therapy. While many rashes are benign, clinicians remain attentive to signs of true allergy, especially in patients with known beta‑lactam sensitivity. Hypersensitivity reactions range from urticaria to more serious presentations, and detailed information is available on the Penicillin Allergy page.
Overall safety considerations, including GI effects, rash, and allergy profiles, are outlined comprehensively in the Side Effects section. Although amoxicillin is widely tolerated, monitoring for unexpected reactions remains essential, particularly when using higher strengths such as 875mg.
Amoxicillin 875mg has several clinically relevant drug interactions that may influence therapeutic outcomes or increase the risk of adverse effects. Co‑administration with warfarin can potentiate anticoagulant activity, requiring careful monitoring due to potential changes in gut flora and vitamin K metabolism. Allopurinol may increase the likelihood of dermatologic reactions, including rash, when used concurrently with amoxicillin, reflecting a well‑documented interaction within beta‑lactam therapy.
Probenecid can elevate amoxicillin serum concentrations by reducing renal tubular secretion, potentially enhancing both efficacy and side‑effect risk. This interaction is sometimes utilized intentionally in clinical settings but requires appropriate oversight. A broader overview of interaction mechanisms and clinical considerations is available in the Interactions section.
Amoxicillin 875mg is preferred in adult patients when infection severity, bacterial burden, or physiological factors suggest that standard strengths may not provide adequate antimicrobial pressure. Individuals with higher body mass may require stronger systemic exposure to achieve effective tissue concentrations, making the 875mg dose a more reliable option. It is also selected when moderate infections begin progressing toward severe presentations or when clinical indicators suggest deeper tissue involvement.
Escalation from 500mg to 875mg is common when symptoms fail to improve, sputum production increases, or inflammation intensifies. In such cases, clinicians choose the higher strength to ensure robust beta‑lactam coverage and reduce the risk of treatment failure. Overall, 875mg is preferred when stronger antimicrobial exposure is necessary to stabilize infection dynamics and support reliable recovery.
Amoxicillin 875mg tablets should be stored in a cool, dry environment to preserve stability and maintain full potency throughout their shelf life. Exposure to moisture, heat, or direct sunlight can degrade the active ingredient or compromise tablet integrity, making proper storage essential. Keeping tablets in their original packaging helps protect them from humidity and accidental contamination.
The solid form of amoxicillin 875mg provides excellent stability compared with liquid formulations, which may require refrigeration or have limited post‑reconstitution shelf life. Tablets maintain structural consistency over time, ensuring predictable dissolution and absorption. Handling should involve avoiding excessive pressure or crushing unless specifically directed, as altering the tablet form may affect pharmacokinetic behavior. Additional general storage guidance is available at the root section Home.